[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fFsQCPxOgN-n3Y-pL5v4eOoJcqNg1FcrSd36818ZYzTg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":60,"rows":67},"University Hospital Southampton NHS Foundation Trust",[4],147,false,36,2,119462,7,116,[14,17,20,23,25,27,29,32],{"name":15,"count":16},"Cardiac Arrest",6,{"name":18,"count":19},"Asthma",5,{"name":21,"count":22},"Heart Failure",4,{"name":24,"count":22},"Critical Illness",{"name":26,"count":22},"Malnutrition",{"name":28,"count":22},"Diffuse Large B Cell Lymphoma",{"name":30,"count":31},"Atrial Fibrillation",3,{"name":33,"count":31},"Post Traumatic Stress Disorder",[35,40,45,50,55],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT02914405","Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed\u002FRefractory Neuroblastoma","2025-06-30","Nivolumab",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06542822","IRONHEART: Intravenous Iron in Non-ischaemic Heart Failure","2026-02","Ferric derisomaltose",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT03552627","Perioperative UtiLisation of SupplEmental Oxygen","2026-12","Oxygen",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06373640","Haemoglobin And Vancomycin Pharmacokinetics in the Cerebrospinal Fluid Following Subarachnoid Haemorrhage","2027-03","Vancomycin",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT04546620","Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)","2027-11","R-CHOP",[61,62,63,64,65,66],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[68,92,126,144,167,185,208,231,257,283,301,328,355,373,416,442,472,496,522,547,565,583,609,627,653,678,705,732,750,775,815,850,868,886,904,922,940,958,976,994,1012,1030,1048,1066,1090,1116,1143,1168],{"intervention":49,"totalTrials":69,"cells":70},1,{"EARLY_PHASE1":71,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":90},{"trials":72,"activeCount":73},[],0,{"trials":75,"activeCount":73},[],{"trials":77,"activeCount":73},[],{"trials":79,"activeCount":73},[],{"trials":81,"activeCount":69,"soonestReadout":48},[82],{"nctId":46,"briefTitle":47,"status":83,"phases":84,"primaryCompletion":48,"completion":48,"start":85,"enrollment":86,"conditions":87,"interventions":89},"ACTIVE_NOT_RECRUITING",[65],"2018-03-01",28,[88],"Anesthesia",[49],{"trials":91,"activeCount":73},[],{"intervention":93,"totalTrials":9,"cells":94},"R-CHOP + acalabrutinib",{"EARLY_PHASE1":95,"PHASE1":97,"PHASE2":99,"PHASE3":120,"PHASE4":122,"NA":124},{"trials":96,"activeCount":73},[],{"trials":98,"activeCount":73},[],{"trials":100,"activeCount":69,"soonestReadout":58},[101,108],{"nctId":56,"briefTitle":57,"status":83,"phases":102,"primaryCompletion":58,"completion":103,"start":104,"enrollment":105,"conditions":106,"interventions":107},[63],"2028-05","2021-10-19",453,[28],[59,93],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":119},"NCT03571308","A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)","COMPLETED",[62,63],"2020-01-02","2023-08-31","2017-06-02",39,[118],"Non Hodgkin Lymphoma",[93],{"trials":121,"activeCount":73},[],{"trials":123,"activeCount":73},[],{"trials":125,"activeCount":73},[],{"intervention":59,"totalTrials":69,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":138,"PHASE4":140,"NA":142},{"trials":129,"activeCount":73},[],{"trials":131,"activeCount":73},[],{"trials":133,"activeCount":69,"soonestReadout":58},[134],{"nctId":56,"briefTitle":57,"status":83,"phases":135,"primaryCompletion":58,"completion":103,"start":104,"enrollment":105,"conditions":136,"interventions":137},[63],[28],[59,93],{"trials":139,"activeCount":73},[],{"trials":141,"activeCount":73},[],{"trials":143,"activeCount":73},[],{"intervention":39,"totalTrials":69,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":159,"PHASE3":161,"PHASE4":163,"NA":165},{"trials":147,"activeCount":73},[],{"trials":149,"activeCount":69,"soonestReadout":38},[150],{"nctId":36,"briefTitle":37,"status":83,"phases":151,"primaryCompletion":38,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":157},[62],"2026-09-30","2018-05-24",44,[156],"Neuroblastoma",[39,158],"Ch14.18\u002FCHO",{"trials":160,"activeCount":73},[],{"trials":162,"activeCount":73},[],{"trials":164,"activeCount":73},[],{"trials":166,"activeCount":73},[],{"intervention":158,"totalTrials":69,"cells":168},{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":177,"PHASE3":179,"PHASE4":181,"NA":183},{"trials":170,"activeCount":73},[],{"trials":172,"activeCount":69,"soonestReadout":38},[173],{"nctId":36,"briefTitle":37,"status":83,"phases":174,"primaryCompletion":38,"completion":152,"start":153,"enrollment":154,"conditions":175,"interventions":176},[62],[156],[39,158],{"trials":178,"activeCount":73},[],{"trials":180,"activeCount":73},[],{"trials":182,"activeCount":73},[],{"trials":184,"activeCount":73},[],{"intervention":54,"totalTrials":69,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":197},{"trials":188,"activeCount":73},[],{"trials":190,"activeCount":73},[],{"trials":192,"activeCount":73},[],{"trials":194,"activeCount":73},[],{"trials":196,"activeCount":73},[],{"trials":198,"activeCount":69,"soonestReadout":53},[199],{"nctId":51,"briefTitle":52,"status":200,"phases":201,"primaryCompletion":53,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":207},"NOT_YET_RECRUITING",[66],"2028-01","2024-11",14,[206],"Subarachnoid Hemorrhage",[54],{"intervention":44,"totalTrials":69,"cells":209},{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":220},{"trials":211,"activeCount":73},[],{"trials":213,"activeCount":73},[],{"trials":215,"activeCount":73},[],{"trials":217,"activeCount":73},[],{"trials":219,"activeCount":73},[],{"trials":221,"activeCount":69,"soonestReadout":43},[222],{"nctId":41,"briefTitle":42,"status":223,"phases":224,"primaryCompletion":43,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":230},"RECRUITING",[],"2027-02","2024-04-15",16,[21,229],"Iron Deficiencies",[44],{"intervention":232,"totalTrials":69,"cells":233},"OMACOR",{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":242,"NA":255},{"trials":235,"activeCount":73},[],{"trials":237,"activeCount":73},[],{"trials":239,"activeCount":73},[],{"trials":241,"activeCount":73},[],{"trials":243,"activeCount":73},[244],{"nctId":245,"briefTitle":246,"status":111,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":254},"NCT00760513","Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids",[65],"2013-11-01","2018-11-29","2009-11-01",103,[253],"Non-Alcoholic Fatty Liver Disease",[232],{"trials":256,"activeCount":73},[],{"intervention":258,"totalTrials":69,"cells":259},"Imodium (Loperamide Hydrochloride) syrup",{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":266,"PHASE4":268,"NA":281},{"trials":261,"activeCount":73},[],{"trials":263,"activeCount":73},[],{"trials":265,"activeCount":73},[],{"trials":267,"activeCount":73},[],{"trials":269,"activeCount":73},[270],{"nctId":271,"briefTitle":272,"status":273,"phases":274,"primaryCompletion":275,"completion":275,"start":276,"enrollment":73,"conditions":277,"interventions":279},"NCT00933465","Imodium Syrup Versus Imodium Tablets for Faecal Incontinence","WITHDRAWN",[65],"2010-05","2009-10",[278],"Fecal Incontinence",[258,280],"Imodium (Loperamide hydrochloride)",{"trials":282,"activeCount":73},[],{"intervention":280,"totalTrials":69,"cells":284},{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":291,"PHASE4":293,"NA":299},{"trials":286,"activeCount":73},[],{"trials":288,"activeCount":73},[],{"trials":290,"activeCount":73},[],{"trials":292,"activeCount":73},[],{"trials":294,"activeCount":73},[295],{"nctId":271,"briefTitle":272,"status":273,"phases":296,"primaryCompletion":275,"completion":275,"start":276,"enrollment":73,"conditions":297,"interventions":298},[65],[278],[258,280],{"trials":300,"activeCount":73},[],{"intervention":302,"totalTrials":69,"cells":303},"capecitabine",{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":310,"PHASE4":324,"NA":326},{"trials":305,"activeCount":73},[],{"trials":307,"activeCount":73},[],{"trials":309,"activeCount":73},[],{"trials":311,"activeCount":73},[312],{"nctId":313,"briefTitle":314,"status":111,"phases":315,"primaryCompletion":316,"start":317,"enrollment":318,"conditions":319,"interventions":323},"NCT00363584","Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer",[64],"2013-08","2006-03",360,[320,321,322],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Liver Cancer",[302],{"trials":325,"activeCount":73},[],{"trials":327,"activeCount":73},[],{"intervention":329,"totalTrials":69,"cells":330},"Intravenous",{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":351,"NA":353},{"trials":332,"activeCount":73},[],{"trials":334,"activeCount":73},[],{"trials":336,"activeCount":73},[],{"trials":338,"activeCount":73},[339],{"nctId":340,"briefTitle":341,"status":111,"phases":342,"primaryCompletion":343,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":349},"NCT01324596","A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib",[64],"2015-04","2015-06","2011-04",1132,[348],"Lymphoma, Large B-Cell, Diffuse",[329,350],"Bortezomib",{"trials":352,"activeCount":73},[],{"trials":354,"activeCount":73},[],{"intervention":350,"totalTrials":69,"cells":356},{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":369,"NA":371},{"trials":358,"activeCount":73},[],{"trials":360,"activeCount":73},[],{"trials":362,"activeCount":73},[],{"trials":364,"activeCount":73},[365],{"nctId":340,"briefTitle":341,"status":111,"phases":366,"primaryCompletion":343,"completion":344,"start":345,"enrollment":346,"conditions":367,"interventions":368},[64],[348],[329,350],{"trials":370,"activeCount":73},[],{"trials":372,"activeCount":73},[],{"intervention":374,"totalTrials":9,"cells":375},"Atezolizumab",{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":410,"PHASE4":412,"NA":414},{"trials":377,"activeCount":73},[],{"trials":379,"activeCount":73},[],{"trials":381,"activeCount":73},[382,398],{"nctId":383,"briefTitle":384,"status":385,"phases":386,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":394},"NCT03422523","Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy","TERMINATED",[63],"2021-01-31","2021-11-18","2018-05-09",53,[28,392,393],"Relapsed Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma",[374,395,396,397],"Rituximab","Gemcitabine 1000 mg","Oxaliplatin 100 MG",{"nctId":399,"briefTitle":400,"status":401,"phases":402,"primaryCompletion":403,"completion":404,"start":405,"enrollment":8,"conditions":406,"interventions":409},"NCT05038657","Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).","UNKNOWN",[63],"2024-01","2025-01","2022-05-30",[407,408],"Squamous Cell Carcinoma","Urinary Tract Cancer",[374],{"trials":411,"activeCount":73},[],{"trials":413,"activeCount":73},[],{"trials":415,"activeCount":73},[],{"intervention":417,"totalTrials":69,"cells":418},"AZD5363",{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":436,"PHASE4":438,"NA":440},{"trials":420,"activeCount":73},[],{"trials":422,"activeCount":73},[],{"trials":424,"activeCount":73},[425],{"nctId":426,"briefTitle":427,"status":111,"phases":428,"primaryCompletion":429,"completion":430,"start":431,"enrollment":432,"conditions":433,"interventions":435},"NCT02121639","Open Label Phase I\u002FRandomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy",[62,63],"2020-10-08","2021-09-13","2014-01-29",160,[434],"Prostate Cancer",[417],{"trials":437,"activeCount":73},[],{"trials":439,"activeCount":73},[],{"trials":441,"activeCount":73},[],{"intervention":443,"totalTrials":69,"cells":444},"p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine",{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":466,"PHASE4":468,"NA":470},{"trials":446,"activeCount":73},[],{"trials":448,"activeCount":73},[],{"trials":450,"activeCount":73},[451],{"nctId":452,"briefTitle":453,"status":111,"phases":454,"primaryCompletion":455,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":465},"NCT01334060","WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation",[63],"2013-02","2013-02-26","2011-02-01",23,[460,461,462,463,464],"Leukaemia (Acute)","Leukaemia (Chronic)","Leukaemia (Acute Myeloid)","Leukaemia (Acute Lymphoblastic)","Leukaemia (Acute Promyelocytic)",[443],{"trials":467,"activeCount":73},[],{"trials":469,"activeCount":73},[],{"trials":471,"activeCount":73},[],{"intervention":473,"totalTrials":69,"cells":474},"Ipilimumab",{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":490,"PHASE4":492,"NA":494},{"trials":476,"activeCount":73},[],{"trials":478,"activeCount":73},[],{"trials":480,"activeCount":73},[481],{"nctId":482,"briefTitle":483,"status":111,"phases":484,"primaryCompletion":344,"completion":344,"start":485,"enrollment":486,"conditions":487,"interventions":489},"NCT01331525","The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer",[63],"2011-06",42,[488],"Extensive Stage Small Cell Lung Cancer",[473],{"trials":491,"activeCount":73},[],{"trials":493,"activeCount":73},[],{"trials":495,"activeCount":73},[],{"intervention":497,"totalTrials":69,"cells":498},"Varlilumab",{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":500,"activeCount":73},[],{"trials":502,"activeCount":73},[],{"trials":504,"activeCount":73},[505],{"nctId":506,"briefTitle":507,"status":111,"phases":508,"primaryCompletion":509,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":515},"NCT03307746","A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma",[62,63],"2021-02-18","2024-08-21","2017-11-23",26,[514],"B Cell Lymphoma",[497],{"trials":517,"activeCount":73},[],{"trials":519,"activeCount":73},[],{"trials":521,"activeCount":73},[],{"intervention":523,"totalTrials":69,"cells":524},"Niraparib Oral Product",{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":529,"PHASE3":541,"PHASE4":543,"NA":545},{"trials":526,"activeCount":73},[],{"trials":528,"activeCount":73},[],{"trials":530,"activeCount":73},[531],{"nctId":532,"briefTitle":533,"status":111,"phases":534,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":540},"NCT05455424","Niraparib Efficacy in Patient With Unresectable Mesothelioma",[63],"2025-01-31","2022-07-11",88,[539],"Mesothelioma, Malignant",[523],{"trials":542,"activeCount":73},[],{"trials":544,"activeCount":73},[],{"trials":546,"activeCount":73},[],{"intervention":396,"totalTrials":69,"cells":548},{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":559,"PHASE4":561,"NA":563},{"trials":550,"activeCount":73},[],{"trials":552,"activeCount":73},[],{"trials":554,"activeCount":73},[555],{"nctId":383,"briefTitle":384,"status":385,"phases":556,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":557,"interventions":558},[63],[28,392,393],[374,395,396,397],{"trials":560,"activeCount":73},[],{"trials":562,"activeCount":73},[],{"trials":564,"activeCount":73},[],{"intervention":397,"totalTrials":69,"cells":566},{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":577,"PHASE4":579,"NA":581},{"trials":568,"activeCount":73},[],{"trials":570,"activeCount":73},[],{"trials":572,"activeCount":73},[573],{"nctId":383,"briefTitle":384,"status":385,"phases":574,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":575,"interventions":576},[63],[28,392,393],[374,395,396,397],{"trials":578,"activeCount":73},[],{"trials":580,"activeCount":73},[],{"trials":582,"activeCount":73},[],{"intervention":584,"totalTrials":69,"cells":585},"Keratinocyte Growth factor",{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":603,"PHASE4":605,"NA":607},{"trials":587,"activeCount":73},[],{"trials":589,"activeCount":73},[],{"trials":591,"activeCount":73},[592],{"nctId":593,"briefTitle":594,"status":111,"phases":595,"primaryCompletion":596,"completion":596,"start":597,"enrollment":598,"conditions":599,"interventions":601},"NCT01386151","A Study to Assess Safety and Efficacy of a Novel Treatment, Keratinocyte Growth Factor (KGF), in Asthmatic Patients",[63],"2011-07","2009-08",24,[600],"Bronchial Asthma",[584,602],"Saline placebo",{"trials":604,"activeCount":73},[],{"trials":606,"activeCount":73},[],{"trials":608,"activeCount":73},[],{"intervention":602,"totalTrials":69,"cells":610},{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":621,"PHASE4":623,"NA":625},{"trials":612,"activeCount":73},[],{"trials":614,"activeCount":73},[],{"trials":616,"activeCount":73},[617],{"nctId":593,"briefTitle":594,"status":111,"phases":618,"primaryCompletion":596,"completion":596,"start":597,"enrollment":598,"conditions":619,"interventions":620},[63],[600],[584,602],{"trials":622,"activeCount":73},[],{"trials":624,"activeCount":73},[],{"trials":626,"activeCount":73},[],{"intervention":628,"totalTrials":69,"cells":629},"Aspirin",{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":647,"PHASE4":649,"NA":651},{"trials":631,"activeCount":73},[],{"trials":633,"activeCount":73},[],{"trials":635,"activeCount":73},[636],{"nctId":637,"briefTitle":638,"status":401,"phases":639,"primaryCompletion":640,"completion":640,"start":641,"enrollment":642,"conditions":643,"interventions":646},"NCT03661463","Unruptured Intracranial Aneurysm Aspirin Trial (UIAAT).",[63],"2019-12","2019-10-24",58,[644,645],"Intracranial Aneurysm","Inflammation",[628],{"trials":648,"activeCount":73},[],{"trials":650,"activeCount":73},[],{"trials":652,"activeCount":73},[],{"intervention":654,"totalTrials":69,"cells":655},"atorvastatin",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":672,"PHASE4":674,"NA":676},{"trials":657,"activeCount":73},[],{"trials":659,"activeCount":73},[],{"trials":661,"activeCount":73},[662],{"nctId":663,"briefTitle":664,"status":111,"phases":665,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":671},"NCT00666029","Implications for Treatment of the Metabolic Syndrome",[63],"2008-02","2006-02",40,[670],"Metabolic Syndrome",[654],{"trials":673,"activeCount":73},[],{"trials":675,"activeCount":73},[],{"trials":677,"activeCount":73},[],{"intervention":679,"totalTrials":69,"cells":680},"Clofarabine",{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":699,"PHASE4":701,"NA":703},{"trials":682,"activeCount":73},[],{"trials":684,"activeCount":73},[],{"trials":686,"activeCount":73},[687],{"nctId":688,"briefTitle":689,"status":111,"phases":690,"primaryCompletion":691,"completion":692,"start":693,"enrollment":694,"conditions":695,"interventions":698},"NCT01422603","Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)",[62,63],"2014-05","2015-03-31","2011-02",9,[696,697],"Acute Myeloid Leukaemia","Myelodysplasia",[679,679],{"trials":700,"activeCount":73},[],{"trials":702,"activeCount":73},[],{"trials":704,"activeCount":73},[],{"intervention":706,"totalTrials":69,"cells":707},"Nitric Oxide",{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":726,"PHASE4":728,"NA":730},{"trials":709,"activeCount":73},[],{"trials":711,"activeCount":73},[],{"trials":713,"activeCount":73},[714],{"nctId":715,"briefTitle":716,"status":111,"phases":717,"primaryCompletion":718,"completion":719,"start":720,"enrollment":721,"conditions":722,"interventions":724},"NCT02295566","RATNO, Reducing Antibiotic Tolerance Using Nitric Oxide in CF - a Phase 2 Pilot Study",[63],"2012-12","2013-07","2011-05",12,[723],"Cystic Fibrosis",[706,725],"Control",{"trials":727,"activeCount":73},[],{"trials":729,"activeCount":73},[],{"trials":731,"activeCount":73},[],{"intervention":725,"totalTrials":69,"cells":733},{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":744,"PHASE4":746,"NA":748},{"trials":735,"activeCount":73},[],{"trials":737,"activeCount":73},[],{"trials":739,"activeCount":73},[740],{"nctId":715,"briefTitle":716,"status":111,"phases":741,"primaryCompletion":718,"completion":719,"start":720,"enrollment":721,"conditions":742,"interventions":743},[63],[723],[706,725],{"trials":745,"activeCount":73},[],{"trials":747,"activeCount":73},[],{"trials":749,"activeCount":73},[],{"intervention":751,"totalTrials":69,"cells":752},"hydrocortisone",{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":757,"PHASE3":769,"PHASE4":771,"NA":773},{"trials":754,"activeCount":73},[],{"trials":756,"activeCount":73},[],{"trials":758,"activeCount":73},[759],{"nctId":760,"briefTitle":761,"status":111,"phases":762,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":768},"NCT00732277","Evaluation of Corticosteroid Therapy in Childhood Severe Sepsis - a Randomised Pilot Study",[63],"2012-04","2008-04",21,[767],"Sepsis",[751],{"trials":770,"activeCount":73},[],{"trials":772,"activeCount":73},[],{"trials":774,"activeCount":73},[],{"intervention":776,"totalTrials":9,"cells":777},"rituximab",{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":788,"PHASE4":790,"NA":792},{"trials":779,"activeCount":73},[],{"trials":781,"activeCount":73},[],{"trials":783,"activeCount":73},[784],{"nctId":383,"briefTitle":384,"status":385,"phases":785,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":786,"interventions":787},[63],[28,392,393],[374,395,396,397],{"trials":789,"activeCount":73},[],{"trials":791,"activeCount":73},[],{"trials":793,"activeCount":73},[794],{"nctId":795,"briefTitle":796,"status":401,"phases":797,"start":798,"enrollment":799,"conditions":800,"interventions":802},"NCT00689845","Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma",[66],"2007-06",120,[801],"Lymphoma",[803,804,776,805,806,807,808,809,810,811,812,813,814],"bleomycin sulfate","filgrastim","cyclophosphamide","cytarabine","doxorubicin hydrochloride","etoposide phosphate","ifosfamide","methotrexate","prednisolone","prednisone","vincristine sulfate","vindesine",{"intervention":816,"totalTrials":9,"cells":817},"Administration of Live attenuated influenza vaccine",{"EARLY_PHASE1":818,"PHASE1":820,"PHASE2":822,"PHASE3":824,"PHASE4":826,"NA":839},{"trials":819,"activeCount":73},[],{"trials":821,"activeCount":73},[],{"trials":823,"activeCount":73},[],{"trials":825,"activeCount":73},[],{"trials":827,"activeCount":73},[828],{"nctId":829,"briefTitle":830,"status":111,"phases":831,"primaryCompletion":832,"completion":833,"start":834,"enrollment":835,"conditions":836,"interventions":838},"NCT02111512","Safety of Nasal Influenza Immunisation in Egg Allergic Children - The SNIFFLE 2 Study",[65],"2015-02","2015-03","2014-09",779,[837],"Egg Hypersensitivity",[816],{"trials":840,"activeCount":73},[841],{"nctId":842,"briefTitle":843,"status":111,"phases":844,"primaryCompletion":845,"completion":845,"start":846,"enrollment":847,"conditions":848,"interventions":849},"NCT01859039","Safety of Nasal Influenza Immunisation in Egg Allergic Children",[],"2014-02","2013-09",282,[837],[816],{"intervention":803,"totalTrials":69,"cells":851},{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":858,"PHASE4":860,"NA":862},{"trials":853,"activeCount":73},[],{"trials":855,"activeCount":73},[],{"trials":857,"activeCount":73},[],{"trials":859,"activeCount":73},[],{"trials":861,"activeCount":73},[],{"trials":863,"activeCount":73},[864],{"nctId":795,"briefTitle":796,"status":401,"phases":865,"start":798,"enrollment":799,"conditions":866,"interventions":867},[66],[801],[803,804,776,805,806,807,808,809,810,811,812,813,814],{"intervention":804,"totalTrials":69,"cells":869},{"EARLY_PHASE1":870,"PHASE1":872,"PHASE2":874,"PHASE3":876,"PHASE4":878,"NA":880},{"trials":871,"activeCount":73},[],{"trials":873,"activeCount":73},[],{"trials":875,"activeCount":73},[],{"trials":877,"activeCount":73},[],{"trials":879,"activeCount":73},[],{"trials":881,"activeCount":73},[882],{"nctId":795,"briefTitle":796,"status":401,"phases":883,"start":798,"enrollment":799,"conditions":884,"interventions":885},[66],[801],[803,804,776,805,806,807,808,809,810,811,812,813,814],{"intervention":805,"totalTrials":69,"cells":887},{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":894,"PHASE4":896,"NA":898},{"trials":889,"activeCount":73},[],{"trials":891,"activeCount":73},[],{"trials":893,"activeCount":73},[],{"trials":895,"activeCount":73},[],{"trials":897,"activeCount":73},[],{"trials":899,"activeCount":73},[900],{"nctId":795,"briefTitle":796,"status":401,"phases":901,"start":798,"enrollment":799,"conditions":902,"interventions":903},[66],[801],[803,804,776,805,806,807,808,809,810,811,812,813,814],{"intervention":806,"totalTrials":69,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":914,"NA":916},{"trials":907,"activeCount":73},[],{"trials":909,"activeCount":73},[],{"trials":911,"activeCount":73},[],{"trials":913,"activeCount":73},[],{"trials":915,"activeCount":73},[],{"trials":917,"activeCount":73},[918],{"nctId":795,"briefTitle":796,"status":401,"phases":919,"start":798,"enrollment":799,"conditions":920,"interventions":921},[66],[801],[803,804,776,805,806,807,808,809,810,811,812,813,814],{"intervention":807,"totalTrials":69,"cells":923},{"EARLY_PHASE1":924,"PHASE1":926,"PHASE2":928,"PHASE3":930,"PHASE4":932,"NA":934},{"trials":925,"activeCount":73},[],{"trials":927,"activeCount":73},[],{"trials":929,"activeCount":73},[],{"trials":931,"activeCount":73},[],{"trials":933,"activeCount":73},[],{"trials":935,"activeCount":73},[936],{"nctId":795,"briefTitle":796,"status":401,"phases":937,"start":798,"enrollment":799,"conditions":938,"interventions":939},[66],[801],[803,804,776,805,806,807,808,809,810,811,812,813,814],{"intervention":808,"totalTrials":69,"cells":941},{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":948,"PHASE4":950,"NA":952},{"trials":943,"activeCount":73},[],{"trials":945,"activeCount":73},[],{"trials":947,"activeCount":73},[],{"trials":949,"activeCount":73},[],{"trials":951,"activeCount":73},[],{"trials":953,"activeCount":73},[954],{"nctId":795,"briefTitle":796,"status":401,"phases":955,"start":798,"enrollment":799,"conditions":956,"interventions":957},[66],[801],[803,804,776,805,806,807,808,809,810,811,812,813,814],{"intervention":809,"totalTrials":69,"cells":959},{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":966,"PHASE4":968,"NA":970},{"trials":961,"activeCount":73},[],{"trials":963,"activeCount":73},[],{"trials":965,"activeCount":73},[],{"trials":967,"activeCount":73},[],{"trials":969,"activeCount":73},[],{"trials":971,"activeCount":73},[972],{"nctId":795,"briefTitle":796,"status":401,"phases":973,"start":798,"enrollment":799,"conditions":974,"interventions":975},[66],[801],[803,804,776,805,806,807,808,809,810,811,812,813,814],{"intervention":810,"totalTrials":69,"cells":977},{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":984,"PHASE4":986,"NA":988},{"trials":979,"activeCount":73},[],{"trials":981,"activeCount":73},[],{"trials":983,"activeCount":73},[],{"trials":985,"activeCount":73},[],{"trials":987,"activeCount":73},[],{"trials":989,"activeCount":73},[990],{"nctId":795,"briefTitle":796,"status":401,"phases":991,"start":798,"enrollment":799,"conditions":992,"interventions":993},[66],[801],[803,804,776,805,806,807,808,809,810,811,812,813,814],{"intervention":811,"totalTrials":69,"cells":995},{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1004,"NA":1006},{"trials":997,"activeCount":73},[],{"trials":999,"activeCount":73},[],{"trials":1001,"activeCount":73},[],{"trials":1003,"activeCount":73},[],{"trials":1005,"activeCount":73},[],{"trials":1007,"activeCount":73},[1008],{"nctId":795,"briefTitle":796,"status":401,"phases":1009,"start":798,"enrollment":799,"conditions":1010,"interventions":1011},[66],[801],[803,804,776,805,806,807,808,809,810,811,812,813,814],{"intervention":812,"totalTrials":69,"cells":1013},{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1018,"PHASE3":1020,"PHASE4":1022,"NA":1024},{"trials":1015,"activeCount":73},[],{"trials":1017,"activeCount":73},[],{"trials":1019,"activeCount":73},[],{"trials":1021,"activeCount":73},[],{"trials":1023,"activeCount":73},[],{"trials":1025,"activeCount":73},[1026],{"nctId":795,"briefTitle":796,"status":401,"phases":1027,"start":798,"enrollment":799,"conditions":1028,"interventions":1029},[66],[801],[803,804,776,805,806,807,808,809,810,811,812,813,814],{"intervention":813,"totalTrials":69,"cells":1031},{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1038,"PHASE4":1040,"NA":1042},{"trials":1033,"activeCount":73},[],{"trials":1035,"activeCount":73},[],{"trials":1037,"activeCount":73},[],{"trials":1039,"activeCount":73},[],{"trials":1041,"activeCount":73},[],{"trials":1043,"activeCount":73},[1044],{"nctId":795,"briefTitle":796,"status":401,"phases":1045,"start":798,"enrollment":799,"conditions":1046,"interventions":1047},[66],[801],[803,804,776,805,806,807,808,809,810,811,812,813,814],{"intervention":814,"totalTrials":69,"cells":1049},{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1056,"PHASE4":1058,"NA":1060},{"trials":1051,"activeCount":73},[],{"trials":1053,"activeCount":73},[],{"trials":1055,"activeCount":73},[],{"trials":1057,"activeCount":73},[],{"trials":1059,"activeCount":73},[],{"trials":1061,"activeCount":73},[1062],{"nctId":795,"briefTitle":796,"status":401,"phases":1063,"start":798,"enrollment":799,"conditions":1064,"interventions":1065},[66],[801],[803,804,776,805,806,807,808,809,810,811,812,813,814],{"intervention":1067,"totalTrials":69,"cells":1068},"Neisseria lactamica",{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1075,"PHASE4":1077,"NA":1079},{"trials":1070,"activeCount":73},[],{"trials":1072,"activeCount":73},[],{"trials":1074,"activeCount":73},[],{"trials":1076,"activeCount":73},[],{"trials":1078,"activeCount":73},[],{"trials":1080,"activeCount":73},[1081],{"nctId":1082,"briefTitle":1083,"status":385,"phases":1084,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":765,"conditions":1087,"interventions":1089},"NCT03549325","A Study Assessing Colonisation & Immunogenicity After Nasal Inoculation With N. Lactamica and Eradication on Day 4 or 14",[66],"2021-12-02","2017-03-13",[1088],"Meningitis, Meningococcal",[1067],{"intervention":1091,"totalTrials":69,"cells":1092},"Prevenar 7 and Prevenar 13",{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1099,"PHASE4":1101,"NA":1103},{"trials":1094,"activeCount":73},[],{"trials":1096,"activeCount":73},[],{"trials":1098,"activeCount":73},[],{"trials":1100,"activeCount":73},[],{"trials":1102,"activeCount":73},[],{"trials":1104,"activeCount":73},[1105],{"nctId":1106,"briefTitle":1107,"status":401,"phases":1108,"primaryCompletion":1109,"completion":1109,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1115},"NCT04401488","Paediatric Post Pneumococcal Conjugate Vaccine Nasopharyngeal Carriage Study",[],"2022-03-31","2014-10-01",4000,[1113,1114],"S. Pneumoniae","Pneumococcal Conjugate Vaccine",[1091],{"intervention":1117,"totalTrials":69,"cells":1118},"Topical Anesthetic",{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1125,"PHASE4":1127,"NA":1129},{"trials":1120,"activeCount":73},[],{"trials":1122,"activeCount":73},[],{"trials":1124,"activeCount":73},[],{"trials":1126,"activeCount":73},[],{"trials":1128,"activeCount":73},[],{"trials":1130,"activeCount":73},[1131],{"nctId":1132,"briefTitle":1133,"status":401,"phases":1134,"primaryCompletion":1135,"completion":1136,"start":1137,"enrollment":1138,"conditions":1139,"interventions":1142},"NCT04102878","Transconjunctival vs Transcutaneous Anaesthesia in Oculoplastics",[66],"2019-10-30","2019-11-30","2019-06-04",30,[1140,1141],"Anesthesia, Local","Eyelid Diseases",[1117],{"intervention":1144,"totalTrials":69,"cells":1145},"MonoFer",{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1152,"PHASE4":1154,"NA":1156},{"trials":1147,"activeCount":73},[],{"trials":1149,"activeCount":73},[],{"trials":1151,"activeCount":73},[],{"trials":1153,"activeCount":73},[],{"trials":1155,"activeCount":73},[],{"trials":1157,"activeCount":73},[1158],{"nctId":1159,"briefTitle":1160,"status":111,"phases":1161,"primaryCompletion":1162,"completion":1162,"start":1163,"enrollment":512,"conditions":1164,"interventions":1167},"NCT03346213","CArdio PulmOnary Exercise Testing and IntRAvenous Iron- 'CAPOEIRA-I STUDY'",[],"2018-10-01","2018-02-02",[1165,1166],"Anemia","Anemia, Iron Deficiency",[1144],{"intervention":1169,"totalTrials":69,"cells":1170},"Mepolizumab",{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1175,"PHASE3":1177,"PHASE4":1179,"NA":1181},{"trials":1172,"activeCount":73},[],{"trials":1174,"activeCount":73},[],{"trials":1176,"activeCount":73},[],{"trials":1178,"activeCount":73},[],{"trials":1180,"activeCount":73},[],{"trials":1182,"activeCount":73},[1183],{"nctId":1184,"briefTitle":1185,"status":401,"phases":1186,"primaryCompletion":1187,"completion":1187,"start":1188,"enrollment":1189,"conditions":1190,"interventions":1192},"NCT04924478","Evaluation of Volatile Organic Compounds in Mepolizumab Therapy",[],"2022-12","2021-07",60,[1191],"Asthma; Eosinophilic",[1169]]